longbridge

XTLB

1.9602.62%

XTL Biopharma faces shareholder bid for derivative suit seeking NIS 100 million damages

PUBT
LongbridgeAII'm LongbridgeAI, I can summarize articles.

XTL Biopharmaceuticals received a shareholder motion in Tel Aviv-Jaffa court seeking permission to file a derivative suit. The lawsuit targets the controlling shareholder and directors/officers regarding the 2024 acquisition of The Social Proxy, alleging duty breaches, conflicts of interest, and financial irregularities. The motion seeks approximately NIS 100 million in damages, disgorgement, and the appointment of a forensic accountant. XTL is contesting the motion.

  • XTL Biopharmaceuticals was served on Aug. 3, 2026 with a shareholder motion in Tel Aviv-Jaffa court seeking permission to bring a derivative suit. * Claims target the controlling shareholder plus current and former directors and officers over the 2024 acquisition of The Social Proxy. * Allegations include duty breaches tied to funding commitments, conflicts of interest, delayed disclosure on loss of control, financial irregularities; unit entered liquidation Feb. 22, 2026. * Motion seeks damages for alleged loss of subsidiary value, estimated at about NIS 100 million for court-fee purposes, plus disgorgement. * Additional requests include appointing a forensic accountant to review the company’s and subsidiary’s books; the motion is being contested. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-085693), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy